A Phase 1, Randomized, Double-Blind, Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001 in Subjects With Atopic Disease

Trial Profile

A Phase 1, Randomized, Double-Blind, Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001 in Subjects With Atopic Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2016

At a glance

  • Drugs AK 001 (Primary)
  • Indications Hypersensitivity
  • Focus Adverse reactions; First in man
  • Sponsors Allakos
  • Most Recent Events

    • 27 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 19 Jan 2016 Status changed from recruiting to active, no longer recruiting, according to an Allakos Inc. media release.
    • 06 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top